American Vanguard Q1 2024 Earnings Call Transcript

Quartr
Provided by Quartr
May 9, 2024

There are 8 speakers on the call.

Operator

Greetings, and welcome to the American Vanguard First Quarter 20 24 Earnings Conference Call and Webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Anthony Young, Director of Investor Relations.

Operator

Thank you. You may begin.

Speaker 1

Thank you, Jesse, and welcome, everyone, to American Vanguard's Q1 2024 earnings review. Our speakers today will be our Chairman and CEO, Eric Wintemute and our CFO, David Johnson. Also joining us to answer your questions will be our Chief Operating Officer, Bob Trogell our Chief Information Officer, Tim Donnelly and our Chief Transformation Officer, Don Caldoni. Before beginning the presentation, let's take a moment for a cautionary reminder. The company from time to time may discuss forward looking information.

Speaker 1

Except for the historical information contained in this release, all forward looking statements are estimates by the company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include weather conditions, changes in regulatory policy and other risks as detailed from time to time in the company's SEC reports and filings. All forward looking statements, if any, in this release present the company's judgment as of the date of this release. With that, I will turn the call over to Eric.

Speaker 2

Thank you, Anthony. Hello, everyone, and welcome to American Vanguard's Q1 2024 earnings call. We appreciate your continued support and interest. As you'll note from Slide 4, I will be covering 4 topics today. Our Q1, twenty twenty four financial performance, current market conditions, our twenty twenty four outlook and our transformation efforts.

Speaker 2

Moving to slide 5 on Q1 performance, we recorded a 35% jump in adjusted EBITDA during the period. In addition, our operating income rose by 87%. This improvement in operating leverage is evidence that the cost control initiatives that we have started in the second half of twenty twenty three are having their desired effect. As I've mentioned in prior calls, our cross functional teams remain focused on controlling expenses, while maximizing operational efficiency. In that vein, we recorded lower operating expenses as a percent of net sales, while increasing sales by 8%.

Speaker 2

Further, all three of our businesses grew during the quarter. Within our consolidated sales results, U. S. Crop was up 9%, U. S.

Speaker 2

Non crop 28% and international 2%. Now let's turn to our sales during Q1 as per Slide 6. In U. S. Crop, we experienced strong results across multiple crops.

Speaker 2

Sales of our granular soil insecticides, Rhodes, which is indicative of continued strong demand from corn growers. Further, we experienced strong sales of our liquid corn soil insecticide index. Similarly, herbicides rose during the period due in part to Dactyl, which was not available last year due to supply issues. Also, Thiamet sales rose with demand driven by increased peanut acreage. These increases were partially offset by a drop in soil fumigant sales as wet conditions in the Northwest truncated the application window.

Speaker 2

Within U. S. Non crop, our mosquito adulticide sales were up in anticipation of stronger than normal tropical storm activity. Also, our sales of pest strips were up significantly as consumer and technical markets recovered from the prior year. In addition, our ornamental nursery business OHP recorded stronger sales led by its biorexional and pre emergent product lines.

Speaker 2

Our international business was up slightly at the top line led by Mexico where most product lines grew and APAC aided by favorable weather conditions in Australia. Our LatAm business was about even for the quarter with the addition of sales from our recently acquired business in Ecuador, partially offset by generic pressure in Central America. All told then, all 3 of our businesses demonstrated improved performance and on a consolidated basis we continue to grow. Before moving on to current market conditions and our 2024 outlook and details on transformation, I'd like to turn the call over to David for his financial analysis. David?

Speaker 3

Thank you, Eric. I will begin my comments with a recap of our Q1 2024 performance, during the course of which I will present important metrics for the period and will close with comments on working capital. As you will see from Slide 8, our overall sales for the 1st 3 months of 2024 increased by about 8% from $125,000,000 to $135,000,000 for the reasons that Eric has already outlined. It is worth repeating here that all three of our businesses, U. S.

Speaker 3

Crop up 9%, U. S. Non crop up 28% and international up 2% grew at the net sales line. Turning to slide 9. While sales were up 8% overall, gross margin dollars improved by 10%, driven by stronger sales of some of our higher margin insecticides and herbicides and the strong factory performance.

Speaker 3

Overall, price volume actions, mix of sales and factory performance resulted in gross margin that improved slightly from 30.8% to 31.4 percent of sales. As you will see on Slide 10, our operating expenses in the Q1 of 2024 edged up to $36,300,000 from $35,300,000 in the same period of 2023. This increase was driven primarily by our spending of $1,200,000 on developing our digital and business transformation plans. We plan to spend more in the next few quarters to invest in the long term future of our business by implementing initiatives to achieve substantial improvement in business performance. We will see some initial improvements in 2024 that are to be largely offset by transformation spending and then primarily benefiting 2025 earnings and beyond.

Speaker 3

In addition, we had increases in general and administrative expenses related to foreign exchange, audit costs, long term and short term incentive compensation and investments in initiatives to improve both our information technology systems and our human resources infrastructure. These cost increases were offset by cost control efforts in selling, regulatory, product development and R and D. With respect to cash flow, as per Slide 11, the company has a pronounced annual cycle of building inventory at the start of the calendar year in order to fuel global sales, particularly during the 2nd and third quarters. It is usual for working capital to expand in the Q1 and Q1 2024 is pretty much in line with the same period of the prior year. We use our revolver debt to fund working capital expansion at the start of the year and pay down as swiftly as possible as the cash cycle completes usually later in the year.

Speaker 3

We have been carefully managing the inventory build as we monitor industry demand trends. At the end of the quarter, we had $13,700,000 in cash as compared to $19,600,000 this time last year. This improvement in reduced amounts of cash held in order to pay down debt is the result of significant effort at the end of the quarter to pull cash back to the corporate center to reduce debt and interest expenses as much as possible. Looking at our statement of operations on Slide 12, you will note that our sales grew by 8%, our gross profit increased by 10% and our operating expenses increased by only 3%. These factors together generated significant improvement in operating leverage with operating income up 87% over the same period of 2023.

Speaker 3

Furthermore, the fair value of our equity instruments improved during the quarter. As a result, profit before interest and tax improved by 107%. Our interest rate increased from 6.8% last year to 8.3% this year, primarily related to movements in the Fed rate, but also as a result of the current modifications we have with our bankers. That includes more flexibility on leverage and fixed charge coverage ratios, but adds about 0.5 percent of interest rate. At the same time, our borrowings are up as a result of our current investment in working capital.

Speaker 3

As I just mentioned, our business cycle is such that we will normally see working capital and consequently debt increasing during Q1 and Q2, possibly leveling to slightly up in Q3 and then significantly significant reduction in Q4 as the growing cycle for our major markets completes its own annual cycle. Our tax rate is higher this quarter primarily as a result of the fact that our entities in Brazil made losses in the Q1 of 2024. Because of Brazil's past business performance, U. S. GAAP does not currently permit us to take the benefit on tax expense that would normally be available.

Speaker 3

As a result of the increased interest expense and the changes in year over year tax expense, our net income is down slightly even though our operating performance and consequently adjusted EBITDA was up significantly. Turning now to working capital on Slide 13. You will see our inventory trends on a quarterly basis for the last several quarters. While inventory grew on an absolute basis in Q1 2024 as compared to Q1 2023. You can see that the increase since Twelvethirty Onetwenty 3 is actually lower than in 2024 than in 2023.

Speaker 3

Further at 39% of net sales, our investment in inventory is similar to the level at this time year. And though we would like to see this balance come down more quickly, it is something we need to manage carefully down, ensuring that we have the right balance of products in inventory to meet customer needs in a timely manner during the 2024 season. During the later part of the year, we plan to move inventory levels down with the intention of reaching a 2024 year end target of around 34% of net sales. That sums up my detailed comments. On the whole, the Q1 of 2024 showed improvement in comparison to the same period of 2023 in terms of both operating income and adjusted EBITDA.

Speaker 3

The company has embarked on an exciting phase of transformation and is managing to invest in a major initiative and still return a profitable result. And as such, I'm quite pleased with the progress we're making in this regard. This initiative will be critically important to the business in the latter part of 2024 and into 2025 and beyond. With that, I turn the call back to Eric. Eric?

Speaker 2

Thank you, David. As for Slide on news of an improving U. S. Economy, the Fed seems to have shifted away from making interest rate hikes and is now debating whether to cut or hold those rates. In addition, the U.

Speaker 2

S. Dollar has begun to strengthen over foreign currencies, While helping consumers with purchasing power over foreign made goods, the strong dollar when coupled with high grain inventory stocks has served to suppress commodity prices compared to 2023. Nevertheless, even as current corn and soybean prices at current levels, farming still remains a profitable business. Further, while still observing conservatism and buying crop inputs, our distribution partners have relaxed their stringent stocking approach from last year at least with respect to our portfolio. In short, the farm economy is strong and we expect stable albeit more deliberate buying activity.

Speaker 2

The same is true of the non crop market where we are seeing further normalization of procurement patterns by retail and professional customers. Now let's turn to slide 15 on our 2024 full year outlook. While market conditions remain stable, there is one factor involving our herbicide Dactyl that causes us to adjust our previous full year targets. In the course of routine registration review, U. S.

Speaker 2

EPA has expressed concern over potential health issues of this product. Accordingly, out of abundance of caution, the company has voluntarily suspended sales of Dactyl and submitted a significantly narrow product label to the agency that we believe addresses their concerns. We have committed to maintaining that suspension of sales pending EPA's review and potential approval of that new label. The outcome of the agency's review is uncertain at present, but we are factoring the loss of Dactyl sales into our 2024 forecast numbers. Accordingly, our full year 2024 targets are as follows.

Speaker 2

We expect next sales to increase between 6% and 9% as compared to 2023, while adjusted EBITDA will be within the range of $60,000,000 to 70,000,000 dollars The midpoint of this range would be a 16% I'm sorry, a 19% increase over 23 adjusted EBITDA. Further, at that midpoint, our stock is currently trading at a discount of nearly 50%, assuming a standard valuation metric of 10 times EBITDA. Let me turn next to our transformation initiatives as per slide 16. On the digital slide, we are working with QAD not only to upgrade their current to their current adaptive global ERP system, but also to standardize our business processes. At the end of this initiative, then all segments will be following the same processes, using the same set of tools and drawing from one source of truth.

Speaker 2

This will give senior management a clear granular view into our business operations and both increase our ability to make real time decisions and to plan and forecast with greater accuracy. On the structural transformation side, we are moving quickly with what we call Project Accelerator. Working with Karn and his team over the next 16 weeks, we'll be doing deep level analysis in several sub initiatives in parallel. Within the commercial realm, we will focus on our sales and marketing strategy, pricing and product mix. Within operation, we will do deep dives into material sourcing, logistics and manufacturing productivity.

Speaker 2

Within G and A, we will select and refine an organization design that best supports our future business plan as well as ensure that these many efforts are managed through a properly resourced transformation office. This broad initiative will generate EBITDA benefits through a range of results including reduced costs, improved efficiencies, emphasis on higher margin products and better defined roles and responsibilities. As I'd stated in our last call, we are confident that we will gain at least $15,000,000 of annualized adjusted EBITDA by 2026 through this investment. In closing, during the quarter, we navigated our business through complex markets while improving operating efficiencies and growing sales. Further, the 2024 market conditions are stable and I would argue stronger than 2023.

Speaker 2

These conditions will serve to generate demand for our products and enable us to improve our inventory and working capital positions. In addition, having begun transformation initiatives in earnest, we are poised to generate even greater operating leverage. In short, we see promising opportunities for growth and are taking strong measures to ensure that we are positioned to capitalize upon them. So with that, I'll turn that back to you, Jesse. Thank you.

Operator

Thank you. Our first question is coming from the line of Scott Fortune with ROTH MKM. Please proceed with your questions.

Speaker 4

Yes, good afternoon and thanks for the question. Just want to follow-up regarding transformation strategy. Nice to see that that's starting to be implemented here. It looks like that will really come through for most of the year. But I heard you say in your comments that any cost savings for 2024 here will be offset by some of the expenses to that.

Speaker 4

So I've really kind of factoring in more of a 2025 to expect that that $15,000,000 inefficiencies $25,000,000 $26,000,000 going forward here. Just want a clarification on that from the operations standpoint.

Speaker 2

Yes, Scott, that's true. So we do have costs to implement and go through this deep dive that we're going through implementation right now. We hope to have we'll have some benefit certainly this year. But as I said, we're projecting that it will overshadow the amount of the transformation. But as we go into 2025, most of the heavy lifting will be done and we'll start seeing getting that $15,000,000 of improved actual EBITDA.

Speaker 4

Got it. That's helpful. So and then just following up on your outlook, obviously, bringing it down to the 6% to 9% from 8% to 12%, that sales side of it. Just kind of step us through Dacto was just getting back on the market from that standpoint, but it's kind of the size of that from a kind of revenue standpoint that's driving that down a little bit? And are there other factors in that sales of 69% outside of Dactyl?

Speaker 4

And then just any color for timing from a historical standpoint kind of as you re register this through the EPA? I know it's just kind of unknown, but your sense of timing for Dactylol coming back on potentially?

Speaker 2

So we submitted the revised label this week. It is a fairly restricted label. We expect EPA to respond fairly quickly. We've been in strong negotiations and discussions with EPA now for well over a year. And we think we've kind of reached where we're going to be.

Speaker 2

And then we discussed pathways of additional information and data that would potentially let us get back at least some of the market that we're not going to have certainly in the short term. So the timing of that, some pieces may be relatively quick, but others could be in that 1 to 3 year timeline depending on the scope of the studies and then the timing for review. As far as scope, this is about a $15,000,000 product. And we had about a third of that in the Q1. And so what we've done is we've just made the assumption we're not going to sell anything more for the balance of the year and we'll factor that.

Speaker 2

We'll have a much clearer picture of what 25 is going to look like soon, certainly before we come up with 'twenty five numbers. And if anything were to change for 'twenty four, we'd certainly adjust it. But at this point, we're not anticipating anything material here in the balance of the year.

Speaker 4

Got it. And I will follow-up on that as far as coming out of the registration process, does that position us even stronger to kind of be a bigger market for you? Or how do you look at that once you get through the process here for the competition and the opportunity for Dactyl?

Speaker 2

Well, Dactyl was growing nicely for us. It's a very, very niche herbicide kind of for kind of cole crops and onions. I don't think we see going back into the onion market, but the cole crops. And so yes, we don't have any assurance that we're going to get back any significant amount of that, but we really have to kind of wait and see. Again, this has been a long process.

Speaker 2

We've been in discussion with the EPA, had a very good call this week, but we're waiting to hear back from them their assessment of what we just submitted.

Speaker 4

Great. And then one last one for me. Any updates on kind of I know the growth kind of products for you, especially the green solutions, we've seen a lot of generic pressure from China in that space, especially impacting Latin America. But of the growth that you've seen for this year and expect in 'twenty four, can you kind of highlight the Green Solutions side and the ongoing product adoption from your standpoint?

Speaker 2

Yes. So, green solutions were up 14% this quarter. And most of the growth I mean most of the areas had growth. And so that seems to be going well. We have additional opportunities for product expansion as we continue to have companies coming to us and saying, hey, with your market access, would you kind of distribute this product and that product?

Speaker 2

So a number of companies there. We did sign up on a Precision plant, a protein called Harbin for the Chinese market. Not sure how big that will be, but this is a product that's been around for quite a while. Monsanto had it at one time. But yes, we see nice growth in that segment as adoption for Green Products continues to build.

Speaker 2

So that's kind of the PureSound brand solutions.

Speaker 4

Appreciate it. Thanks for all the color and I'll jump back in the queue.

Operator

Thank you. Our next question is coming from the line of Chris Kapsch with Loop Capital Markets. Please proceed with your question.

Speaker 5

Yes. Good afternoon. I have a couple. Just as a follow-up on the Dactyl discussion. Eric, if I remember correctly, was this the product that you mentioned you've been in discussions with the agency for over a year.

Speaker 5

If I remember correctly, that also manifested in disruption to your sourcing the AI for this particular product. And I thought that the outcome of that was that you came to resolution. So it's a little surprising to hear this cautious stance in re registration now. And just wondering what are the risks associated with getting this to a favorable outcome and how are you managing that?

Speaker 2

Yes. So the 2 different issues, 1 was supply and we didn't have supply for a year. And so that we have resolved and we have actually 2 supply sources. So the supply side was certainly taken care of. On the re registration process, a different path with EPA and we're not necessarily in agreement on their assessment, but rather than push that further with them, we went as far as we think we can go for right now and we believe we've submitted a revised label that they should accept, but that will be certainly a reduction of the market that we've had.

Speaker 2

So as far as the timing is kind of as I anticipated, we've got different stages of pieces that we would like to reinstate. And first piece, as I mentioned, we think will be relatively short. The next 2 kind of run-in between 1 2 years and then maybe between 2 3. And not sure that we're happy that we're going to wind up doing all of it. We'll assess the market and when as we get further information from EPA.

Speaker 5

Got it. And the cost associated with these sorts of studies and re registrations, is that just sort of normal course of business and factored into your R and D spend, your normal R and D spend?

Speaker 2

That's correct.

Speaker 5

Got it. And then, so just curious about this year's sort of the mood of the growers and the trends in the Midwest. And we came off of what was described related to another company on file as the most mild winter in like 25 years. And so sometimes when that happens, there's the infestation of the insects is greater. So I'm curious if you there's any evidence that was the case for corn rootworm pressure this season?

Speaker 5

Are you seeing any indications that you could have an uptrend in demand for your soil applied insecticides?

Speaker 2

I'll let Bob add some color, but I'll just say I'm talking with my people. Yes, there are wet conditions particularly in. So planting at this point is maybe in the 50% range with the south there, but there's large parts of the corn and soybean market that have not been planted yet. So it is an extended period. But Bob, your color?

Speaker 6

Yes. I would say, Chris, the mood has been very cautious by the growers in the Midwest and the U. S. I think there's been this past week a little bit of a pickup in the July corn and soybean pricing, which people are locking into that and averaging out better if they're doing forward pricing and contracting. So the mood has picked up.

Speaker 6

So I think there's more optimism out there. But you do have pockets right now where people were planting, someone told me this morning, a grower told me it was like April 16, he had about 90% of his planting done. And since then, he has been able to get back in the field because it's been wet. So he sets out 10% to go. And that's a long window of not stop and go.

Speaker 6

So there's a little bit of that, but that's normal for the ag markets. Weather is weather.

Speaker 2

Yes. With regard to the corn root worm pressure, so Astec and to some degree counter and force are primarily used in that heavier pressure corn rootworm area. We haven't really participated in the kind of mild to mid corn rootworm pressure. But we have a new product that we put out a couple of years ago, but we just haven't had enough material. We make it internally, but demand has gone faster than we've been able to produce.

Speaker 2

But we had good production and sales in the Q1 up until I think we were up until April 17th, 18th or whatever we were selling product. And we're building inventory now for kind of the 4th quarter because we do have we did have stronger demand than what we had supply, but we're thinking we can kind of dramatically increase. And this is again, it's a liquid material. So it kind of competes with bifenthrin in that market. And so that's an upside for us going forward.

Speaker 2

Much more acreage covered are treated for mild to medium corn rootworm pressure than heavy pressure.

Speaker 5

That's helpful. And then last question. So your herbicide impact is often used sort of to complement some of the workforce broad spectrum herbicides. And just curious like given what had happened with global supply chain and the supply tightness with glyphosate globally and the spike in those prices kind of normalized in terms of pricing and availability and some of the kind of normalized in terms of pricing and availability and some of the cash from crop herbicides? Thanks.

Speaker 5

And then how that affects your impact sales and how does that play out in your guidance and expectations this year? Thank you.

Speaker 2

I mean, I think you recall that herbicides were kind of a glut that prices were high in 2022 and came down in 2023 and there was a high inventory and high price out there. It seems to have improved. But if I look at looking at larger peers, 1st quarter was not good for them. So I think there's probably still some hangover into that herbicide market.

Operator

We don't

Speaker 2

have the kind of large bulk scale, although we do have impact with grosphosphonate as a product. And so, yes, again, impact has been more a tank mix partner than a main horse. But it looks improved versus last year.

Speaker 5

Is there any way to quantify that the improvement like what's factored into your outlook on that particular product? And then

Speaker 4

I'll leave

Speaker 5

it at that. Thanks.

Speaker 2

We were just about even to last year. I think we had good 4th quarter sales versus the prior year. It looks like we're about even in the Q1.

Speaker 3

And then

Speaker 2

Q2 looks considerably stronger than last year's Q2.

Speaker 5

Thank you.

Operator

Thank you. Our next question comes from the line of Andrew Lester with Harlan Capital. Please proceed with your question.

Speaker 7

Hi. Thank you for taking the question. If I'm reading it correctly and forgive me if I'm off by this, 18 months ago or 24 months ago, you sounded very optimistic. You laid out some exciting timelines and information. And even in the last year or so, again, you sounded very clear on ways to enhance value, do board refreshes, all sorts of things that we were pointing to as milestones to lead to significantly better results.

Speaker 7

And when I listen to you today, you sound very tentative, equivocal and really uncertain and looking for really a more significant improvement without quantification for like a year from now. Is that a fair read? Have you become much more cautious about your prospects?

Speaker 2

Well, I would say that we are pointing towards improvement with through the transformation process, but that has an expense of transferring now. It's one time expense. But yes, as we've mentioned before that we've grown through acquisitions of companies from since 2017 and we did not get the benefit of incorporating those the way we wanted to and hampered certainly during COVID. But the process now is that we put underway is to get all the systems on the same page so that we can do better management and where we deploy working capital and improve the quality. And as I said, our target here, I think we're maybe 11.5% of EBITDA to sales.

Speaker 2

What we're looking through this transformation process is to improve that EBITDA margin to 15%.

Speaker 7

But if I look at things, just a follow-up on a sort of more mercenary basis as a shareholder, I'm probably down over 40% in the past year. How do you think or when do you expect things to translate into better equity performance?

Speaker 2

Well, I think we're up a little over 14% so far this year. As we mentioned last year, we were hit with 2 supply issues that really hurt us. 1 was our biggest insecticide and the second was the supply of Dactyl that we mentioned. So we've improved the sourcing or the sourcing on both of those. We have ample material of Astec going forward.

Speaker 2

And so that was really a hit to Q4 of 2022 and certainly to the 2023 and we were unable to meet demand. Supply wise, we're in a different position and we're back to moving Astec and now Index and Force and Smart Choice back up into the corn market. So I guess, I mean, I look at what where our peers have been discussing, they forecasted downsides in Q1 and that turned out to be the case. We did have improvements in Q1. And so we've made the forecast based upon the best that we can see at this point.

Speaker 7

Okay. Thank you for your time.

Operator

Thank you. Ladies and gentlemen, it appears we have no additional questions at this time. So I'd like to turn the floor back over to Mr. Wintemute for any additional closing remarks.

Speaker 2

Okay. So thank you for all for listening in today. Provide updates as we have them. But I guess the next scheduled time would be our shareholders meeting, which I believe is June 6 or 7? 6.

Speaker 2

Yes. Okay. Thank you and have a good evening. Bye.

Operator

Ladies and gentlemen, this does conclude today's teleconference. We thank you for your participation and you may disconnect your lines at this time.

Powered by Quartr

Key Takeaways

  • Strong Q1 results with 8% sales growth, 35% jump in adjusted EBITDA and an 87% increase in operating income driven by cost-control and operational efficiency initiatives.
  • All three business segments expanded in Q1: U.S. Crop sales were up 9%, U.S. Non-Crop rose 28%, and International grew 2%.
  • The voluntary suspension of Dactyl herbicide pending EPA label revisions is expected to cut roughly $15 million of 2024 sales, leading to full-year guidance of 6–9% sales growth and $60–70 million in adjusted EBITDA.
  • Investments in transformation—including a global ERP upgrade and Project Accelerator—added $1.2 million of Q1 costs but are targeted to deliver at least $15 million of annualized EBITDA by 2026.
  • Working capital build in Q1 tracked seasonal norms; the company ended the quarter with $13.7 million in cash and used repatriated funds to reduce debt and interest expense.
AI Generated. May Contain Errors.
Earnings Conference Call
American Vanguard Q1 2024
00:00 / 00:00